SB/Incyte molecular diagnostics venture targeting infectious disease, oncology test development.
This article was originally published in The Gray Sheet
Executive SummaryDIADEXUS' HOME BREW REAGENTS TO ENTER CLINICAL USE IN NEXT 1-3 YEARS, SmithKline Beecham estimates. SmithKline and Incyte Pharmaceuticals announced Sept. 2 formation of joint venture diaDexus to pursue development of molecular in vitro diagnostics.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.